OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS
OS Therapies (NYSE American: OSTX), a clinical-stage biopharmaceutical company, has been accepted into Johnson & Johnson Innovation – JLABS. The company aims to develop its tunable Antibody Drug Conjugate (ADC) linker-based platform at JLABS. This platform uses pH sensitive linkers & coating technology to reduce off-target effects, potentially improving safety and increasing the diversity of therapeutic payloads delivered.
OS Therapies' goal is to offer improved efficacy compared to other ADCs in the market or in development. The company's unique linker platform allows for the creation of new intellectual property for both novel and off-patent targeting antibodies and drug payloads. This development could potentially lead to more effective and safer ADC-based therapies in the future.
OS Therapies (NYSE American: OSTX), un'azienda biofarmaceutica in fase clinica, è stata accettata in Johnson & Johnson Innovation – JLABS. L'azienda si propone di sviluppare la sua piattaforma basata su coniugati di farmaci ad anticorpi (ADC) a legami regolabili presso JLABS. Questa piattaforma utilizza legami sensibili al pH e tecnologie di rivestimento per ridurre gli effetti off-target, potenzialmente migliorando la sicurezza e aumentando la diversità dei carichi terapeutici forniti.
Il nostro obiettivo è offrire un'efficacia migliorata rispetto ad altri ADC sul mercato o in fase di sviluppo. La piattaforma unica dei legami dell'azienda consente la creazione di nuove proprietà intellettuali per anticorpi e carichi terapeutici mirati sia innovativi che in scadenza di brevetto. Questo sviluppo potrebbe portare a terapie basate su ADC più efficaci e sicure in futuro.
OS Therapies (NYSE American: OSTX), una empresa biofarmacéutica en etapa clínica, ha sido aceptada en Johnson & Johnson Innovation – JLABS. La empresa tiene como objetivo desarrollar su plataforma basada en conjugados de medicamentos con anticuerpos (ADC) ajustables en JLABS. Esta plataforma utiliza enlaces sensibles al pH y tecnología de recubrimiento para reducir los efectos fuera de objetivo, mejorando potencialmente la seguridad y aumentando la diversidad de cargas terapéuticas entregadas.
El objetivo de OS Therapies es ofrecer una eficacia mejorada en comparación con otros ADC en el mercado o en desarrollo. La plataforma de enlaces única de la empresa permite la creación de nueva propiedad intelectual para anticuerpos dirigidos tanto novedosos como fuera de patente. Este desarrollo podría llevar a terapias basadas en ADC más efectivas y seguras en el futuro.
OS Therapies (NYSE American: OSTX)는 임상 단계의 생명공학 회사로, Johnson & Johnson Innovation – JLABS에 수락되었습니다. 이 회사는 JLABS에서 조정 가능한 항체 약물 접합체(ADC) 링커 기반 플랫폼을 개발하는 것을 목표로 하고 있습니다. 이 플랫폼은 pH 감응 링커 및 코팅 기술을 사용하여 비표적 효과를 줄여 안전성을 개선하고 전달되는 치료제의 다양성을 증가시킬 수 있습니다.
OS Therapies의 목표는 시장 또는 개발 중인 다른 ADC들과 비교하여 개선된 효능을 제공하는 것입니다. 회사의 독특한 링커 플랫폼은 신규 및 특허 만료된 표적 항체 및 약물 칼로리를 위한 새로운 지적 재산을 생성할 수 있게 합니다. 이 개발은 미래에 더 효과적이고 안전한 ADC 기반 치료로 이어질 수 있습니다.
OS Therapies (NYSE American: OSTX), une entreprise biopharmaceutique en phase clinique, a été acceptée dans Johnson & Johnson Innovation – JLABS. L'entreprise vise à développer sa plateforme de conjugés de médicaments par anticorps (ADC) à liaison réglable au sein de JLABS. Cette plateforme utilise des liens sensibles au pH et une technologie de revêtement pour réduire les effets hors cible, améliorant ainsi la sécurité et augmentant la diversité des charges thérapeutiques livrées.
L'objectif d'OS Therapies est d'offrir une efficacité améliorée par rapport aux autres ADC sur le marché ou en développement. La plateforme unique de liaison de l'entreprise permet de créer de nouvelles propriétés intellectuelles tant pour des anticorps ciblés novateurs que pour des charges médicamenteuses hors brevet. Ce développement pourrait potentiellement mener à des thérapies basées sur des ADC plus efficaces et plus sûres à l'avenir.
OS Therapies (NYSE American: OSTX), ein biopharmazeutisches Unternehmen in klinischer Phase, wurde in Johnson & Johnson Innovation – JLABS aufgenommen. Das Unternehmen hat sich zum Ziel gesetzt, seine anpassbare Antikörper-Wirkstoff-Konjugat (ADC) Linker-basierte Plattform bei JLABS zu entwickeln. Diese Plattform nutzt pH-sensitive Linker & Beschichtungstechnologie, um off-target-Effekte zu reduzieren, was potenziell die Sicherheit verbessert und die Vielfalt der gelieferten therapeutischen Lasten erhöht.
Das Ziel von OS Therapies ist es, eine verbesserte Wirksamkeit im Vergleich zu anderen auf dem Markt befindlichen oder in Entwicklung befindlichen ADCs anzubieten. Die einzigartige Linker-Plattform des Unternehmens ermöglicht die Schaffung von neuen geistigen Eigentumsrechten für sowohl neuartige als auch patentfreie zielgerichtete Antikörper und Wirkstofflastern. Diese Entwicklung könnte in der Zukunft zu effektiveren und sichereren auf ADC basierenden Therapien führen.
- Acceptance into Johnson & Johnson Innovation - JLABS, potentially providing valuable resources and networking opportunities
- Development of a tunable ADC linker-based platform with potential for improved safety and efficacy
- Opportunity to create new intellectual property for both novel and off-patent targeting antibodies and drug payloads
- None.
- Focus of work at JLABS on tunable Antibody Drug Conjugate linker-based platform
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma, with results expected in the fourth quarter of 2024. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing strong preclinical efficacy data in various models of breast cancer. In addition, OS Therapies is advancing its next generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company’s proprietary silicone linker technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the offer and sale of shares, the timing of the listing of OS Therapies’ common stock on the NYSE American, the timing of the closing of the offering, the use of the proceeds from the sale of shares of common stock in the offering, and the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those described under the caption “Risk Factors” and elsewhere in the prospectus filed with the SEC relating to the offering and that actual results may differ materially from those indicated by such forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240819756213/en/
Corporate and Media:
Jack Doll
410-297-7793
Irpr@ostherapies.com
Investor Relations:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
OSTX@redchip.com
Source: OS Therapies
FAQ
What is the significance of OS Therapies (OSTX) being accepted into Johnson & Johnson Innovation - JLABS?
What is the main focus of OS Therapies (OSTX) at JLABS?
How does OS Therapies (OSTX) aim to improve upon existing ADC therapies?
